Compare LOPE & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOPE | GPCR |
|---|---|---|
| Founded | 1949 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 2008 | 2023 |
| Metric | LOPE | GPCR |
|---|---|---|
| Price | $160.97 | $20.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $194.00 | $105.78 |
| AVG Volume (30 Days) | 266.6K | ★ 1.2M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $511,257,000.00 | N/A |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $6.15 | N/A |
| P/E Ratio | $35.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $134.27 | $21.55 |
| 52 Week High | $223.04 | $94.90 |
| Indicator | LOPE | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 66.75 | 13.66 |
| Support Level | $160.00 | N/A |
| Resistance Level | $175.09 | $56.63 |
| Average True Range (ATR) | 3.83 | 1.58 |
| MACD | 0.68 | -0.28 |
| Stochastic Oscillator | 88.16 | 2.01 |
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges, both online and on the ground at its campus in Phoenix, Arizona, and at four off-site classroom andlaboratory sites. The Company generates all of its revenue through service agreements with its university partners.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.